{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:46:25Z","timestamp":1786653985588,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","award":["2024-0040"],"award-info":[{"award-number":["2024-0040"]}],"id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008368","name":"Gigtforeningen","doi-asserted-by":"publisher","award":["A6158"],"award-info":[{"award-number":["A6158"]}],"id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","award":["A3650"],"award-info":[{"award-number":["A3650"]}],"id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","painmanagementnursing.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pain Management Nursing"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pmn.2026.07.020","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:15:58Z","timestamp":1786533358000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6279-9522","authenticated-orcid":false,"given":"Maria Juul","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Bjarke","family":"Vaegter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-2461","authenticated-orcid":false,"given":"Karin Due","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pmn.2026.07.020_bib0001","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/ar2783","article-title":"The Revised Fibromyalgia Impact Questionnaire (FIQR): Validation and psychometric properties","volume":"11","author":"Bennett","year":"2009","journal-title":"Arthritis Research & Therapy"},{"issue":"4","key":"10.1016\/j.pmn.2026.07.020_bib0002","doi-asserted-by":"crossref","DOI":"10.1097\/PR9.0000000000001080","article-title":"Low-dose naltrexone for treatment of pain in patients with fibromyalgia: A randomized, double-blind, placebo-controlled, crossover study","volume":"8","author":"Bested","year":"2023","journal-title":"PAIN Reports"},{"issue":"3","key":"10.1016\/j.pmn.2026.07.020_bib0003","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life","volume":"72","author":"Brown","year":"2009","journal-title":"Medical Hypotheses"},{"issue":"1","key":"10.1016\/j.pmn.2026.07.020_bib0004","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1186\/s13063-021-05776-7","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial","volume":"22","author":"Bruun","year":"2021","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.pmn.2026.07.020_bib0005","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","article-title":"Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: A randomised, double-blind, placebo-controlled trial","volume":"6","author":"Bruun","year":"2024","journal-title":"Lancet Rheumathology"},{"issue":"9","key":"10.1016\/j.pmn.2026.07.020_bib0006","article-title":"Pregabalin for pain in fibromyalgia in adults","volume":"9","author":"Derry","year":"2016","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1016\/j.pmn.2026.07.020_bib0007","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/biomedicines11041087","article-title":"Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: A fourteen-year, enterprise-wide retrospective analysis","volume":"11","author":"Driver","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.pmn.2026.07.020_bib0008","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","article-title":"Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: A randomised, double-blind, placebo-controlled trial","volume":"6","author":"Due Bruun","year":"2024","journal-title":"The Lancet Rheumatology"},{"issue":"1","key":"10.1016\/j.pmn.2026.07.020_bib0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3344\/kjp.25275","article-title":"Low-dose naltrexone for fibromyalgia: A re-analysis suggests lower efficacy than previously reported","volume":"39","author":"Due Bruun","year":"2026","journal-title":"The Korean Journal of Pain"},{"issue":"3","key":"10.1016\/j.pmn.2026.07.020_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.pmn.2026.07.020_bib0011","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00296-017-3725-2","article-title":"Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis","volume":"37","author":"Heidari","year":"2017","journal-title":"Rheumatology International"},{"issue":"6","key":"10.1016\/j.pmn.2026.07.020_bib0012","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/j.pain.0000000000002475","article-title":"Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations","volume":"163","author":"Kleykamp","year":"2022","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pmn.2026.07.020_bib0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00207454.2019.1664510","article-title":"Duloxetine for pain in fibromyalgia in adults: A systematic review and a meta-analysis","volume":"130","author":"Lian","year":"2020","journal-title":"The International Journal of Neuroscience"},{"issue":"1","key":"10.1016\/j.pmn.2026.07.020_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/15360288.2024.2302550","article-title":"Efficacy and safety of low dose naltrexone for chronic pain","volume":"38","author":"Irwin","year":"2024","journal-title":"Journal of Pain & Palliative Care Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.pmn.2026.07.020_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR revised recommendations for the management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pmn.2026.07.020_bib0016","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2147\/JPR.S451183","article-title":"Effective doses of low-dose naltrexone for chronic pain\u2014An observational study","volume":"17","author":"Marcus","year":"2024","journal-title":"Journal of Pain Research"},{"key":"10.1016\/j.pmn.2026.07.020_bib0017","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3899\/jrheum.110277","article-title":"Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update","volume":"38","author":"Mease","year":"2011","journal-title":"The Journal of Rheumatology"},{"issue":"3","key":"10.1016\/j.pmn.2026.07.020_bib0018","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/15360288.2025.2496526","article-title":"Efficacy of low-dose naltrexone in treating patients with fibromyalgia: Systematic review and meta-analysis","volume":"39","author":"Ologunowa","year":"2025","journal-title":"Journal of Pain & Palliative Care Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.pmn.2026.07.020_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines5020016","article-title":"Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia","volume":"5","author":"Parkitny","year":"2017","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.pmn.2026.07.020_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15638","article-title":"A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia","volume":"9","author":"Partridge","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.pmn.2026.07.020_bib0021","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11916-020-00898-0","article-title":"Low-dose naltrexone for chronic pain: Update and systemic review","volume":"24","author":"Phillip","year":"2020","journal-title":"Current Pain and Headache Reports"},{"key":"10.1016\/j.pmn.2026.07.020_bib0022","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41584-020-00506-w","article-title":"Fibromyalgia: An update on clinical characteristics, aetiopathogenesis and treatment","volume":"16","author":"Sarzi-Puttini","year":"2020","journal-title":"Nature Reviews Rheumatology"},{"issue":"8","key":"10.1016\/j.pmn.2026.07.020_bib0023","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.3390\/ijms22083891","article-title":"Fibromyalgia: Pathogenesis, mechanisms, diagnosis and treatment options update","volume":"22","author":"Siracusa","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/j.pmn.2026.07.020_bib0024","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"2","key":"10.1016\/j.pmn.2026.07.020_bib0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1016\/j.pmn.2026.07.020_bib0026","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clinical Rheumatology"}],"container-title":["Pain Management Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904226002560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904226002560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:07:26Z","timestamp":1786651646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1524904226002560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"alternative-id":["S1524904226002560"],"URL":"https:\/\/doi.org\/10.1016\/j.pmn.2026.07.020","relation":{},"ISSN":["1524-9042"],"issn-type":[{"value":"1524-9042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial","name":"articletitle","label":"Article Title"},{"value":"Pain Management Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmn.2026.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Pain Management Nursing.","name":"copyright","label":"Copyright"}]}}